Pfizer closes in on $7.3bn takeover of anti-obesity drugmaker Metsera
Deal would be the biggest by a large pharma company buying a foothold in the lucrative weight-loss drug market
Related reading
Pfizer wins $10bn bidding war for weight-loss start-up Metsera
Biotech says it opted for revised offer from US pharma company after rival Novo bid raised antitrust concerns
Battle for obesity biotech Metsera heats up as Pfizer sues to block rival bid
FTC fast-tracks antitrust approval of earlier deal in sign Washington could weigh in on takeover battle with Novo Nordisk
Novo Nordisk again raises bid in battle for obesity start-up Metsera
Danish company vies with Pfizer for control of US biotech as they seek edge in growing market for weight-loss drugs
Pfizer shows hardball mettle needed to win in 2025 M&A
Pharma giant had to pay a blockbuster price to buy Metsera after the biotech prospect spurred an auction with Novo Nordisk
Novo Nordisk gatecrashes Pfizer deal with $9bn bid for Metsera
Pfizer had struck deal in September to buy obesity-focused biotech
Weight-loss wars: $10bn hostile battle pits Pfizer against Novo Nordisk
Two groups fight for edge in one of the most lucrative drug classes in pharmaceutical industry history